What to expect in the Edgewise Therapeutics, Inc. interview process

Based on publicly available sources, Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Boulder, Colorado, with a distributed workforce across the United States, United Kingdom, and Switzerland.

Operating in the biotechnology research sector, the company focuses on creating novel precision medicines for rare muscle disorders, muscular dystrophies, and serious cardiac conditions, with key therapeutic candidates including Sevasemten and EDG-7500. Public company records show that Edgewise has experienced steady headcount growth as it scales its operations, expanding from 19 employees in 2020 to an estimated 110–146 employees between 2024 and 2025. The firm went public via an IPO in 2021, has raised significant venture backing (totaling approximately $145M to $160.5M across funding rounds from investors such as New Leaf Venture Partners, Citadel, and OrbiMed), and commands a market capitalization in the billions.

While financial results, market valuation, and pipeline developments (such as clinical trials and broker recommendations) are publicly tracked, the available source data does not contain specific first-person employee testimonials, day-to-day workplace culture details, management styles, or concrete descriptions of internal hiring and interview processes.